Browse > Article
http://dx.doi.org/10.1016/j.jgr.2016.11.004

Effect of Korean Red Ginseng in chronic liver disease  

Park, Tae Young (Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine)
Hong, Meegun (Department of Internal Medicine, Hallym University College of Medicine)
Sung, Hotaik (Department of Molecular and Cell Physiology, University of Cincinnati College of Medicine)
Kim, Sangyeol (Department of Internal Medicine, Hallym University College of Medicine)
Suk, Ki Tae (Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine)
Publication Information
Journal of Ginseng Research / v.41, no.4, 2017 , pp. 450-455 More about this Journal
Abstract
Chronic liver disease, one of the most common diseases, typically arises from nonalcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, or hepatocellular carcinoma. Therefore, there is a pressing need for improved treatment strategies. Korean Red Ginseng has been known to have positive effects on liver disease and liver function. In this paper, we summarize the current knowledge on the beneficial effects of Korean Red Ginseng on chronic liver disease, a condition encompassing nonalcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, and hepatocellular carcinoma, as supported by experimental evaluation and clinical investigation.
Keywords
alcoholic liver disease; hepatic C virus; hepatocellular carcinoma; nonalcoholic liver disease; Panax ginseng;
Citations & Related Records
Times Cited By KSCI : 10  (Citation Analysis)
연도 인용수 순위
1 Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008;48:670-8.   DOI
2 Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011;8:491-501.   DOI
3 Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract 2010:2010.
4 Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58-61.   DOI
5 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.   DOI
6 Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350:1142-3.
7 Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, et al. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol 2016;22:160-7.   DOI
8 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142. 1264-73 e1.   DOI
9 Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, Heo JY, Park SJ, Park YM. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol 2016;22:339-49.   DOI
10 Kim WR, Brown Jr RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-42.
11 Sanyal AJ. NASH: a global health problem. Hepatol Res 2011;41:670-4.   DOI
12 Yun TK, Choi SY, Yun HY. Epidemiological study on cancer prevention by ginseng: are all kinds of cancers preventable by ginseng? J Korean Med Sci 2001;16(Suppl):S19-27.   DOI
13 Yun TK, Yun YS, Han IW. Anticarcinogenic effect of long-term oral administration of red ginseng on newborn mice exposed to various chemical carcinogens. Cancer Detect Prev 1983;6:515-25.
14 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.   DOI
15 Lee SM, Bae BS, Park HW, Ahn NG, Cho BG, Cho YL, Kwak YS. Characterization of Korean Red Ginseng (Panax ginseng Meyer): history, preparation method, and chemical composition. J Ginseng Res 2015;39:384-91.   DOI
16 Heo SB, Lim SW, Jhun JY, Cho ML, Chung BH, Yang CW. Immunological benefits by ginseng through reciprocal regulation of Th17 and Treg cells during cyclosporine-induced immunosuppression. J Ginseng Res 2016;40:18-27.   DOI
17 Lee MJ, Jang M, Choi J, Chang BS, Kim do Y, Kim SH, Kwak YS, Oh S, Lee JH, Chang BJ, et al. Korean Red Ginseng and ginsenoside-Rb1/-Rg1 alleviate experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells. Mol Neurobiol 2016;53:1977-2002.   DOI
18 Bang CS, Hong SH, Suk KT, Kim JB, Han SH, Sung H, Kim EJ, Kim MJ, Kim MY, Baik SK, et al. Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhus vernicifera Stokes), and probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut-liver axis of alcoholic liver disease. J Ginseng Res 2014;38:167-72.   DOI
19 Kim P, Park JH, Kwon KJ, Kim KC, Kim HJ, Lee JM, Kim HY, Han SH, Shin CY. Effects of Korean Red Ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid. Food Chem Toxicol 2013;51:288-96.   DOI
20 Hong SH, Suk KT, Choi SH, Lee JW, Sung HT, Kim CH, Kim EJ, Kim MJ, Han SH, Kim MY, et al. Anti-oxidant and natural killer cell activity of Korean Red Ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. Food Chem Toxicol 2013;55:586-91.   DOI
21 Jeong TC, Kim HJ, Park JI, Ha CS, Park JD, Kim SI, Roh JK. Protective effects of red ginseng saponins against carbon tetrachloride-induced hepatotoxicity in Sprague Dawley rats. Planta Med 1997;63:136-40.   DOI
22 Lee MH, Lee BH, Lee S, Choi C. Reduction of hepatitis A virus on FRhK-4 cells treated with Korean Red Ginseng extract and ginsenosides. J Food Sci 2013;78:M1412-5.   DOI
23 Xie J-T, Mehendale SR, Li X, Quigg R, Wang X, Wang C-Z, Wu JA, Aung HH, A Rue P, Bell GI, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta 2005;1740:319-25.   DOI
24 Lee SH, Jung BH, Kim SY, Lee EH, Chung BC. The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol Res 2006;54:46-9.   DOI
25 Yun TK. Panax ginseng-a non-organ-specific cancer preventive? Lancet Oncol 2001;2:49-55.   DOI
26 Han JY, Lee S, Yang JH, Kim S, Sim J, Kim MG, Jeong TC, Ku SK, Cho IJ, Ki SH. Korean Red Ginseng attenuates ethanol-induced steatosis and oxidative stress via AMPK/Sirt1 activation. J Ginseng Res 2015;39:105-15.   DOI
27 Paul S, Shin HS, Kang SC. Inhibition of inflammations and macrophage activation by ginsenoside-Re isolated from Korean ginseng (Panax ginseng C.A. Meyer). Food Chem Toxicol 2012;50:1354-61.   DOI
28 Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Reof Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;550:173-9.   DOI
29 Park HM, Kim SJ, Mun AR, Go HK, Kim GB, Kim SZ, Jang SI, Lee SJ, Kim JS, Kang HS. Korean Red Ginseng and its primary ginsenosides inhibit ethanol-induced oxidative injury by suppression of the MAPK pathway in TIB-73 cells. J Ethnopharmacol 2012;141:1071-6.   DOI
30 Bak MJ, Jun M, Jeong WS. Antioxidant and hepatoprotective effects of the red ginseng essential oil in $H_2O_2$-treated hepG2 cells and $CCl_4$-treated mice. Int J Mol Sci 2012;13:2314-30.   DOI
31 Lee HJ, Ok HM, Kwon O. Protective effects of Korean Red Ginseng against alcohol-induced fatty liver in rats. Molecules 2015;20:11604-16.   DOI
32 Seo SJ, Cho JY, Jeong YH, Choi YS. Effect of Korean Red Ginseng extract on liver damage induced by short-term and long-term ethanol treatment in rats. J Ginseng Res 2013;37:194-200.   DOI
33 Kim HJ, Chun YJ, Park JD, Kim SI, Roh JK, Jeong TC. Protection of rat liver microsomes against carbon tetrachloride-induced lipid peroxidation by red ginseng saponin through cytochrome P450 inhibition. Planta Med 1997;63:415-8.   DOI
34 Kim H, Hong MK, Choi H, Moon HS, Lee HJ. Chemopreventive effects of Korean Red Ginseng extract on rat hepatocarcinogenesis. J Cancer 2015;6:1-8.   DOI
35 Abdel-Wahhab MA, Hassan NS, El-Kady AA, Khadrawy YA, El-Nekeety AA, Mohamed SR, Sharaf HA, Mannaa FA. Red ginseng extract protects against aflatoxin B1 and fumonisins-induced hepatic pre-cancerous lesions in rats. Food Chem Toxicol 2010;48:733-42.   DOI
36 Kim YS, Kim YH, Noh JR, Cho ES, Park JH, Son HY. Protective effect of Korean Red Ginseng against aflatoxin B1-induced hepatotoxicity in rat. J Ginseng Res 2011;35:243-9.   DOI
37 Wu XG, Zhu DH, Li X. Anticarcinogenic effect of red ginseng on the development of liver cancer induced by diethylnitrosamine in rats. J Korean Med Sci 2001;16(Suppl):S61-5.   DOI
38 Abdel-Wahhab MA, Gamil K, El-Kady AA, El-Nekeety AA, Naguib KM. Therapeutic effects of Korean Red Ginseng extract in Egyptian patients with chronic liver diseases. J Ginseng Res 2011;35:69-79.   DOI
39 Hong M, Lee YH, Kim S, Suk KT, Bang CS, Yoon JH, Baik GH, Kim DJ, Kim MJ. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res 2016;40:203-10.   DOI
40 Kwon YS, Jang KH. The effect of Korean Red Ginseng on liver regeneration after 70% hepatectomy in rats. J Vet Med Sci 2004;66:193-5.   DOI
41 Xu X, Ling Q, Wei Q, Wang K, Zhou B, Zhuang L, Zhou L, Zheng S. Korean Red Ginseng: a new approach for the treatment of graft-versus-host disease after liver transplantation. Transplant Proc 2011;43:2651-5.   DOI
42 Kwon YS, Jang KH, Jang IH. The effects of Korean Red Ginseng (ginseng radix rubra) on liver regeneration after partial hepatectomy in dogs. J Vet Sci 2003;4:83-92.
43 Ki SH, Yang JH, Ku SK, Kim SC, Kim YW, Cho IJ. Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. J Ginseng Res 2013;37:45-53.   DOI
44 Qi LW, Wang CZ, Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep 2011;28:467-95.   DOI
45 Hong M, Lee YH, Kim S, Suk KT, Bang CS, Yoon JH, Baik GH, Kim DJ, Kim MJ. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res 2015.
46 Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T. [Chemical studies of crude drugs (1). Constituents of ginseng radix rubra.]. Yakugaku Zasshi 1983;103:612-22.   DOI
47 Huu Tung N, Uto T, Morinaga O, Kim YH, Shoyama Y. Pharmacological effects of ginseng on liver functions and diseases: a minireview. Evid Based Complement Alternat Med 2012;2012:173297.
48 Chen J, Peng H, Ou-Yang X, He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res 2008;18:322-9.   DOI
49 He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, et al. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ss-catenin signaling. Int J Oncol 2011;38:437-45.
50 Luo X, Wang CZ, Chen J, Song WX, Luo J, Tang N, He BC, Kang Q, Wang Y, Du W, et al. Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol 2008;32:975-83.
51 Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 2009;32:755-65.   DOI
52 Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS, Kwon SW, Park JH. Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 2009;73:811-6.   DOI
53 Zhang Q, Kang X, Yang B, Wang J, Yang F. Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharmaceut 2008;23:647-53.   DOI
54 XuTM, CuiMH,Xin Y,Gu LP, Jiang X, SuMM,WangDD,Wang WJ. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J 2008;121:1394-7.
55 Xu TM, Xin Y, Cui MH, Jiang X, Gu LP. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J 2007;120:584-8.
56 Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 2004;27:429-35.   DOI
57 Lu P, Su W, Miao ZH, Niu HR, Liu J, Hua QL. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 2008;14:33-6.   DOI
58 Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 2009;9:250.   DOI
59 Zhang C, Liu L, Yu Y, Chen B, Tang C, Li X. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 2012;5:1295-8.
60 Jiang JW, Chen XM, Chen XH, Zheng SS. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol 2011;17:3605-13.   DOI
61 Lee HU, Bae EA, Han MJ, Kim DH. Hepatoprotective effect of 20(S)-ginsenosides Rg3 and its metabolite 20(S)-ginsenoside Rh2 on tert-butyl hydroperoxide-induced liver injury. Biol Pharm Bull 2005;28:1992-4.   DOI
62 Shuangyan W, Ruowu S, Hongli N, Bei Z, Yong S. Protective effects of Rg2 on hypoxia-induced neuronal damage in hippocampal neurons. Artif Cells Blood Substit Immobil Biotechnol 2012;40:142-5.   DOI
63 Yuan HD, Kim do Y, Quan HY, Kim SJ, Jung MS, Chung SH. Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3beta via AMP-activated protein kinase to inhibit hepatic glucose production in HepG2 cells. Chem Biol Interact 2012;195:35-42.   DOI
64 Ha SE, Shin DH, Kim HD, Shim SM, Kim HS, Kim BH, Lee JS, Park JK. Effects of ginsenoside Rg2 on the ultraviolet B-induced DNA damage responses in HaCaT cells. Naunyn Schmiedebergs Arch Pharmacol 2010;382:89-101.   DOI
65 Li N, Liu B, Dluzen DE, Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007;111:458-63.   DOI
66 Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis 2012;30(Suppl 1):61-8.   DOI
67 LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Penaranda MM, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014;48:467-73.
68 Atabek ME. Non-alcoholic fatty liver disease and metabolic syndrome in obese children. World J Gastroenterol 2011;17:4445-6.   DOI
69 Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenter Hepatol 2007;22(Suppl 1):S20-7.   DOI